Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Name (Synonyms) | Correlation | |
---|---|---|
drug1570 | Icosapent ethyl Wiki | 0.71 |
drug2448 | Placebo Wiki | 0.05 |
Name (Synonyms) | Correlation | |
---|---|---|
D050197 | Atherosclerosis NIH | 1.00 |
D002318 | Cardiovascular Diseases NIH | 0.17 |
D012141 | Respiratory Tract Infections NIH | 0.17 |
Name (Synonyms) | Correlation | |
---|---|---|
HP:0002621 | Atherosclerosis HPO | 1.00 |
HP:0011947 | Respiratory tract infection HPO | 0.17 |
HP:0001626 | Abnormality of the cardiovascular system HPO | 0.17 |
Navigate: Correlations HPO
There is one clinical trial.
This is a randomized, double-blind, placebo-controlled study that will enroll subjects with a clinical diagnosis of COVID-19 confirmed by laboratory testing and who are in severe or critical condition as indicated by life-support measures.
Description: Number of adverse events from start of treatment
Measure: Safety of CAP-1002 Time: 90 daysDescription: Cytokine absolute values and changes from start of treatment to Day 30.
Measure: Efficacy of CAP-1002 on Cytokine Time: 30 daysDescription: Biomarker absolute values and changes from start of treatment to Day 30.
Measure: Efficacy of CAP-1002 on Laboratory Biomarker Time: 30 daysDescription: Number of all cause mortality cases within 30 days from start of treatment
Measure: All cause mortality Time: 30 daysDescription: Number of Intensive Care Unit (ICU) discharges within 30 days from start of treatment
Measure: ICU Discharge Time: 30 daysDescription: Duration in ICU from start of treatment (up to 90 days)
Measure: Duration in ICU Time: 90 daysDescription: Number of hospital discharges within 30 days from start of treatment
Measure: Hospital Discharge Time: 30 daysDescription: Duration in hospital from start of treatment up to Day 90
Measure: Hospitalization length Time: 90 daysDescription: Duration of time on supplemental oxygen or mechanical ventilation from start of treatment up to Day 90
Measure: Ventilatory status Time: 90 daysDescription: Severity of ARDS as defined by the Berlin criteria, absolute values and changes from start of treatment to Day 30.
Measure: Acute Respiratory Distress Time: 30 daysDescription: Absolute values and changes from start of treatment to Day 30.
Measure: Ordinal Scale of Clinical Improvement Time: 30 daysDescription: Time to a 1-point decrease (indicative of improvement) on the WHO Ordinal Scale of Clinical Improvement from start of treatment
Measure: WHO Ordinal Improvement Time: 90 daysDescription: Area under the severity versus time curve, where severity is defined by the Ordinal Scale of Clinical Improvement and time is measured from start of treatment to Day 30
Measure: Severity vs. Time Time: 30 daysAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports